Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Administration officials say South Africa has “significant means” to fund a promising new drug, lenacapavir, on its own.
About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were delivered to Zambia and Eswatini last Thursday, U.S. and ...
Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...
To put this spike into perspective, the rural city of around 32,000 people has now recorded more HIV cases in two years than ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...
BILLYPENNGRAM OF THE DAY “Stand tall, wear a crown, be sweet on the inside, prickly on the outside.”(Photo by @philahistory) ...
Eswatini on Tuesday became the first African country to receive lenacapavir, the first twice-yearly HIV prevention injection hailed by global health officials as a game-changer in the fight against a ...
A federal jury in Fort Lauderdale has convicted two Maryland brothers of orchestrating a multimillion-dollar scheme to buy and resell<a class="excerpt-read-more" href=" More ...
Stocktwits on MSN
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study
The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results